← Leaderboards
Keith R. McCrae
Case Western Reserve University
$18,540,560
Attributed
$23,238,219
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,238,219 · 11
By mechanism
R01$9,281,327 · 5
U01$6,458,455 · 2
UH3$3,845,395 · 1
T32$2,050,459 · 1
UG3$876,052 · 1
U34$726,531 · 1
Top collaborators
- Alok A Khorana8 shared
- Mukesh Kumar Jain4 shared
- Claudia Marcela Diaz-Montero3 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Alvin H Schmaier$10,124,403
Others in their field
Top investigators on “Plasma”
- David Heimbrook · Leidos Biomedical Research, Inc.$170,532,526
- Barton F Haynes · Duke University$119,611,088
- Paul S. Aisen · Cognition Therapeutics, Inc.$110,079,727
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,527,289
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$85,429,770
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$78,577,996
Research focus
PlasmaReportingBlood VesselsResponseMorbidity - Disease RatePathway InteractionsGenerationsEndothelial CellsKininogensThrombosisAngiogenesisCoagulation ProcessMediatingMalignant NeoplasmsProteinsRegulationSamplingClinical TrialsCohortPreventAngiogenesis InhibitorsNovel StrategiesApoptosisClinical Research
Grant awards (49)
Mechanisms of cancer immunotherapy-associated thrombosis$720,736
R01 · FY2025 · HL · contact PI
Mechanisms of cancer immunotherapy-associated thrombosis$704,368
R01 · FY2024 · HL · contact PI
Mechanisms of cancer immunotherapy-associated thrombosis$721,398
R01 · FY2023 · HL · contact PI
1/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT)$618,148
UH3 · FY2023 · HL · contact PI
Novel approaches to improve prediction of cancer-associated thrombosis$957,703
U01 · FY2022 · HL · contact PI
1/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT)$887,209
UH3 · FY2022 · HL · contact PI
1/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT)$1,170,955
UH3 · FY2021 · HL · contact PI
Novel approaches to improve prediction of cancer-associated thrombosis$967,487
U01 · FY2021 · HL · contact PI
1/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT)$1,169,083
UH3 · FY2020 · HL · contact PI
Novel approaches to improve prediction of cancer-associated thrombosis$960,071
U01 · FY2020 · HL · contact PI
Novel approaches to improve prediction of cancer-associated thrombosis$953,390
U01 · FY2019 · HL · contact PI
1/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT)$876,052
UG3 · FY2019 · HL · contact PI
Novel approaches to improve prediction of cancer-associated thrombosis$905,594
U01 · FY2018 · HL · contact PI
Transcriptional control of endothelium in APS by Kruppel Like factors$448,951
R01 · FY2017 · HL · contact PI
Transcriptional control of endothelium in APS by Kruppel Like factors$448,951
R01 · FY2016 · HL · contact PI
Efficacy of Pomalidomide in HHT-related bleeding$233,628
U34 · FY2016 · HL · contact PI
Transcriptional control of endothelium in APS by Kruppel Like factors$442,217
R01 · FY2015 · HL · contact PI
Efficacy of Pomalidomide in HHT-related bleeding$236,594
U34 · FY2015 · HL · contact PI
Transcriptional control of endothelium in APS by Kruppel Like factors$448,951
R01 · FY2014 · HL · contact PI
Efficacy of Pomalidomide in HHT-related bleeding$256,309
U34 · FY2014 · HL · contact PI
Regulation of Angiogenesis by Kininogen$373,431
R01 · FY2013 · HL · contact PI
Regulation of Angiogenesis by Kininogen$396,089
R01 · FY2012 · HL · contact PI
Transfusion Medicine/Hemostasis Clinical Research Network$28,260
U01 · FY2012 · HL · contact PI
Regulation of Angiogenesis by Kininogen$398,915
R01 · FY2011 · HL · contact PI
Regulation of Angiogenesis by Kininogen$326,946
R01 · FY2010 · HL · contact PI
Hematology Training Grant$153,446
T32 · FY2010 · HL · contact PI
Regulation of Angiogenesis by Kininogen$82,204
R01 · FY2010 · HL · contact PI
Regulation of Angiogenesis by Kininogen$431,750
R01 · FY2009 · HL · contact PI
Transfusion Medicine/Hemostasis Clinical Research Network$193,000
U01 · FY2009 · HL · contact PI
Hematology Training Grant$80,966
T32 · FY2009 · HL · contact PI
Hematology Training Grant$425,957
T32 · FY2008 · HL · contact PI
Hematology Training Grant$502,035
T32 · FY2007 · HL · contact PI
Tropomyosin in the antiangiogenic activity of HKa$327,221
R01 · FY2007 · HL · contact PI
Hematology Training Grant$444,373
T32 · FY2006 · HL · contact PI
Tropomyosin in the antiangiogenic activity of HKa$336,993
R01 · FY2006 · HL · contact PI
Transfusion Medicine/Hemostasis Clinical Research Netwo*$292,950
U01 · FY2006 · HL · contact PI
Tropomyosin in the antiangiogenic activity of HKa$345,103
R01 · FY2005 · HL
Transfusion Medicine/Hemostasis Clinical Research Netwo*$300,000
U01 · FY2005 · HL
Hematology Training Grant$293,035
T32 · FY2005 · HL
ANTI ANGIOGENIC ACTIVITY OF CLEAVED HMW KININOGEN$403,905
R01 · FY2004 · CA
Tropomyosin in the antiangiogenic activity of HKa$358,353
R01 · FY2004 · HL
Transfusion Medicine/Hemostasis Clinical Research Netwo*$300,000
U01 · FY2004 · HL
Hematology Training Grant$150,647
T32 · FY2004 · HL
ANTI ANGIOGENIC ACTIVITY OF CLEAVED HMW KININOGEN$394,965
R01 · FY2003 · CA
Transfusion Medicine/Hemostasis Clinical Research Netwo*$300,000
U01 · FY2003 · HL
ANTI ANGIOGENIC ACTIVITY OF CLEAVED HMW KININOGEN$409,056
R01 · FY2002 · CA
Transfusion Medicine/Hemostasis Clinical Research Netwo*$300,000
U01 · FY2002 · HL
ANTI ANGIOGENIC ACTIVITY OF CLEAVED HMW KININOGEN$399,963
R01 · FY2001 · CA
ANTI ANGIOGENIC ACTIVITY OF CLEAVED HMW KININOGEN$360,861
R01 · FY2000 · CA